#ESMO26 | GUARD-01 (Phase II)
Neoadjuvant disitamab vedotin + gemcitabine in HER2+ MIBC:
pCR: 62.5% (15/24) 3-year EFS: 78.1% after cystectomy Promising long-term outcomes! Phase III GUARD-02 is ongoing. @SCUColombia @achoHematoYOnco @myESMO @ASCO @OncoAlert @oncodaily 🦾🦾